Despite the drug having a 90-minute half-life, patients maintained and even saw continued improvement eight months after stopping the 12-week treatment. This suggests the drug facilitates genuine neural repair and rewiring, rather than offering only temporary symptomatic relief that requires continuous dosing.

In a counterintuitive medical choice, some individuals with healthy but underperforming limbs (e.g., a twisted foot) fight to have them amputated. They recognize that a well-designed modern prosthetic can provide more mobility and a better quality of life than their natural, but chronically dysfunctional, anatomy.

Don't wait until Phase 3 to think about commercialization. Biotech firms must embed secondary endpoints in Phase 2 trials that capture quality of life and patient journey insights. This data is critical for building a compelling value proposition that resonates with payers and secures market access.

To be effective, the patient's lived experience cannot remain a "soft narrative." It must be converted into hard data points—like reduced healthcare utilization for payers or influence on treatment pathways for clinicians—to become a decision-making tool they cannot ignore.

Beyond tackling fatal diseases to increase lifespan, a new wave of biotech innovation focuses on "health span"—the period of life lived in high quality. This includes developing treatments for conditions often dismissed as aging, such as frailty, vision loss, and hearing decline, aiming to improve wellbeing in later decades.

Contrary to the belief that recovery is limited to the months post-injury, NervGen's trial specifically enrolled and showed significant functional improvement in patients with chronic injuries, some a decade old. This opens a new treatment window for a large, previously overlooked patient population.

Biotech leaders must stop viewing commercialization as a post-approval task. The critical window is Phase 2 clinical trials. By embedding patient journey and quality of life insights into secondary endpoints, companies can build a compelling value proposition for payers and physicians. Waiting until Phase 3 is too late.

To help a participant with ALS who couldn't use voice commands to pause the BCI cursor, Neuralink created the "parking spot," a visual gesture-based toggle. This solution, designed for a specific edge case, was immediately adopted by all other participants as a superior, universally valuable feature.

The company first targets patients with disabilities, a clear medical need. By restoring functions like speech, they create platforms for enhanced abilities (e.g., prompting AI with thoughts), paving the way for a wider consumer market where the risk-benefit calculation shifts over time.